CD4CAR for CD4+ Leukemia and Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2040

Conditions
T-cell LymphomaT-cell Leukemia
Interventions
BIOLOGICAL

CD4CAR

CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose

Trial Locations (4)

10467

RECRUITING

Albert Einstein Health Network, New York

11794

ACTIVE_NOT_RECRUITING

Stony Brook Cancer Center, Stony Brook

33136

RECRUITING

University of Miami Sylvester Comprehensive Cancer Center, Miami

46202

RECRUITING

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

iCell Gene Therapeutics

INDUSTRY

lead

Huda Salman

OTHER

NCT03829540 - CD4CAR for CD4+ Leukemia and Lymphoma | Biotech Hunter | Biotech Hunter